cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Avidity Biosciences Inc
4 own
6 watching
Current Price
$10.9
$-0.03
(-0.27%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
771.86M
52-Week High
52-Week High
25.74
52-Week Low
52-Week Low
9.83
Average Volume
Average Volume
0.51M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
-12.91379688
iconMarket Capitalization771.86M
icon52-Week High25.74
icon52-Week Low9.83
iconAverage Volume0.51M
iconDividend Yield--
iconP/E Ratio-12.91379688
What does the Avidity Biosciences Inc do?
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company s lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Read More
How much money does Avidity Biosciences Inc make?
News & Events about Avidity Biosciences Inc.
Globe Newswire
1month ago
NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. (Avidity or the Company) (NASDAQ: RNA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The ...
PR Newswire
1month ago
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44...
Globe Newswire
1month ago
ATLANTA, April 20, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Avidity Biosciences, Inc. (Avidityor the Company) (NASDAQ: RNA) complied with federal securities laws. On March 30, 2023, Avidity provided an update on its product that is on a partial clinical hold for new ...
PR Newswire
1month ago
Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting PR Newswire SAN DIEGO, April 17, 2023 SAN DIEGO, April 17, 2023 /PRNewswire...
PR Newswire
1month ago
Avidity Biosciences to Host Investor and Analyst Event Focused on AOC 1001 Topline Data from Phase 1/2 MARINA Trial on April 27, 2023 Avidity Biosciences to Host Investor and Analyst Event Focused on AOC 1001 Topline Data from Phase 1/2 MARINA Trial on April 27, 2023 PR Newswire SAN DIEGO...
Frequently Asked Questions
Frequently Asked Questions
What is Avidity Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Avidity Biosciences Inc shares?
plus_minus_icon
How can I buy Avidity Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Avidity Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Avidity Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Avidity Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Avidity Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Avidity Biosciences Inc?
plus_minus_icon
What percentage is Avidity Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Avidity Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$10.9
$-0.03
(-0.27%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
CADRE HOLDINGS
CADRE HOLDINGS
$21.14
$0.14 (0.67 %)
Archer Aviation Inc
Archer Aviation Inc
$3.06
$0.16 (5.52 %)
Quanterix Corporation
Quanterix Corporation
$20.79
$0.03 (0.14 %)
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.
$5.53
$0.06 (1.10 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
CADRE HOLDINGS
CADRE HOLDINGS
$21.14
$0.14 (0.67 %)
Archer Aviation Inc
Archer Aviation Inc
$3.06
$0.16 (5.52 %)
Quanterix Corporation
Quanterix Corporation
$20.79
$0.03 (0.14 %)
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.
$5.53
$0.06 (1.10 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00